Category archive


Comparing Blood-Thinners for Atrial Fibrillation

Apixaban [Eliquis] scores highest of all the NOACs, “on the balance of efficacy, safety and cost.” Pharmacy News December 5, 2017 Which NOAC scores highest for atrial fibrillation? New ranking may help guide decision-making Apixaban is the most efficient non-vitamin K oral anticoagulant (NOAC) for treating atrial fibrillation, according to the results of a meta-analysis including 95,000 patients from 23 randomised controlled trial. There’s already a large body of evidence that NOACs are at least as effective as warfarin and…

Keep Reading

FDA: Atrial Fibrillation and New Oral Anticoagulant Drugs

From the US Food and Drug Administration October 2016 Ellis F. Unger, M.D. More than 3 million Americans have atrial fibrillation, a problem with the electrical system of the heart that causes an irregular heart rhythm. Atrial fibrillation can produce palpitations, shortness of breath, lightheadedness, weakness, and chest pain, or may occur without symptoms. The main concern, however, is that atrial fibrillation can lead to the formation of blood clots in the heart, which can travel to the brain and…

Keep Reading

Reversing the Effects of the New Anti-Clotting Drugs

Though catastrophic bleeding from the novel oral anticoagulants is extremely rare, the availability of antidotes reassures health care providers, patients, and their families. It changes the psychology of prescribing and tilts the balance more strongly toward the novel agents. Harvard Health Blog –December 9, 2018\6 –Samuel Z. Goldhaber, MD The oral anticoagulant warfarin (Coumadin) became available for prescription in 1954. This anti-clotting drug commanded national attention when President Dwight Eisenhower received the drug as part of his treatment following a…

Keep Reading

Xarelto Approved for Treatment of Atrial Fibrillation (2011)

Source: Xarelto Approved by the FDA for Atrial Fibrillation Stroke Prevention November 4, 2011 By Mellanie True Hills Summary: The FDA has approved a second alternative to warfarin, Xarelto (rivaroxaban), for stroke prevention in atrial fibrillation. The U.S. Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those who have non-valvular atrial fibrillation (afib that is not related to heart valve problems). Xarelto becomes the second oral alternative to warfarin and is considered a good…

Keep Reading

Jury orders Drug Companies to pay $28 million in Xarelto lawsuit

A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers’ failure to warn of internal bleeding risks from their blood thinner Xarelto.– (Reuters) – Tina Bellon– The verdict marks the first trial loss in litigation over Xarelto. Bayer and J&J have won three previous cases in federal court. Bayer in a statement said it believed there was no basis for the verdict, including the punitive…

Keep Reading

Grapefruit and Xarelto: Use Grapefruit in Moderation

Does grapefruit interact with Xarelto (rivaroxaban)? Beth Waldron, Program Director of Clot Connect, writes…. The claim: In a recent newspaper article (ref 1), it was stated that “grapefruit eaten in ordinary amounts can interact harmfully with some common prescription drugs”. Among the drugs listed is the oral anticoagulant Xarelto® (rivaroxaban). Xarelto was approved by the FDA on November 2, 2012 for the treatment and prevention of deep vein thrombosis and pulmonary embolism. The FDA-approved prescribing information makes no mention of…

Keep Reading

Go to Top